New Haven’s Rallybio reported promising results in a Phase 1 study of its drug candidate RLYB212, designed for the prevention of a serious blood disease in fetuses and newborns.
A monoclonal antibody, RLYB212 can prevent the development of fetal and neonatal alloimmune thrombocytopenia, a potentially fatal rare disease that can cause uncontrolled bleeding due to immune incompatibility between maternal and fetal platelets.